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The choice of optimal ﬁrst-line chemotherapy for advanced ovarian
cancer continues to excite controversy. In the late 1990s the wide-
spread recognition that carboplatin represented a less toxic and
equally efﬁcacious alternative to cisplatin was a major step forward.
At the same time, the introduction of paclitaxel appeared to be a
signiﬁcant advance, based on a survival beneﬁt in two large rando-
mised trials, i.e. GOG1-11 and OVO-10 (McGuire et al, 1996;
Piccart et al, 2000). Funding difﬁculties were eventually resolved
in the UK by a positive NICE assessment 2 years ago, conﬁrming
the role of paclitaxel in ﬁrst-line combination therapy.
Since then, however, doubts have arisen, largely over two rando-
mised trials, GOG 132 and ICON 3, which essentially indicate that
single agent platinum therapy is as effective as paclitaxel-platinum
combination. These seemingly conﬂicting data are well described
and discussed in the review in this journal issue, by Sandercock
et al. They propose that the likeliest explanation of these data is
that the control arms differed substantially; cyclophosphamide-
cisplatin being less effective than the other options. They conclude
that ‘single agent carboplatin is a safe and effective ﬁrst-line treat-
ment for women with advanced ovarian cancer.’
The data as described would be compatible with the notion
that cyclophosphamide-cisplatin represented a suboptimal control
arm; nevertheless it did represent standard treatment in many
centres until the mid 1990s and this was based on other trials
showing the beneﬁt compared to single agent platinum. If the
authors are correct in their assertion, some further consideration
of this explanation would have been helpful. Biochemical antag-
onism between cyclophosphamide and platinum at the tumour
cell itself has been suggested although seems unlikely, but it is
conceivable that some aspect of the platinum dose is relevant.
In both GOG 1-11 and OVO-10, cyclophosphamide-induced toxi-
city led to a greater number of delays in treatment in that arm,
compared to the paclitaxel arms, resulting in signiﬁcantly lower
cisplatin dose-intensities actually received. Whilst reviews of
various trials indicate that increasing dose-intensity for platinum
has doubtful beneﬁt (Vasey et al, 1998), it is possible that reduc-
tions below an optimal threshold could well lead to an inferior
result.
Although it is hard to contradict the authors’ concluding state-
ment, those of us involved in managing this disease clearly need to
go forwards rather than backwards from here. Further detailed
comparisons of these four studies done at different times by differ-
ent groups using different treatments can be useful in formulating
hypotheses, but any conclusions should be drawn with caution, not
least because of the heterogeneity of treated populations. Taxanes
should remain an important element in the ﬁrst line of manage-
ment of these patients, for several reasons. There is clear
evidence of efﬁcacy in patients whose disease no longer responds
to platinum, implying that the target cancer cell population is
somewhat different, and this is supported by experimental data
focusing on the presence or absence of functional p53 (Wahl et
al, 1996). In addition, the mechanism of action and the toxicity
proﬁles are quite different from platinum. For virtually all chemo-
sensitive epithelial cancers, combination chemotherapy rather than
single agent treatment has provided signiﬁcant survival beneﬁts
when applied as initial therapy, and there seems no fundamental
reason for concluding that ovarian cancer will ultimately prove
to be different in this regard. The challenge now remains: how
to identify the optimal combination?
The two trials, GOG 132 and ICON 3, do suggest that pacli-
taxel-cisplatin or paclitaxel-carboplatin, given as concurrent treat-
ments every 3 weeks for 6 cycles with a 24 h or three paclitaxel
infusion may not necessarily be the best approach. It is conceivable,
indeed, that the two drugs exhibit a degree of antagonism in
certain schedules, and experimental data on this are equivocal.
Alternative approaches should clearly be considered for clinical
trial research and these could include sequential regimes, in which
the taxanes and the platinum compound are given separately. The
impact of modulators of response to chemotherapy, such as EGFR
tyrosine kinase inhibitors, also merits serious consideration, since
they may have an important effect on any taxane-platinum interac-
tions. These and other approaches, such as the further evaluation
of ‘maintenance chemotherapy’ with single agent paclitaxel, and
the incorporation of other active agents such as liposomal doxo-
rubicin, topotecan and gemcitabine provide a rich seam for clinical
triallists in the next few years.
Meantime, the management of the individual patient outside a
clinical trial will continue to excite debate. Although clinical prac-
tices are not uniform, it is probably true to say that for some
clinicians the threshold for withholding paclitaxel from ﬁrst line
therapy may have changed as a result of GOG 132 and ICON 3.
As pointed out by Sandercock et al, a pooling of the overall data
utilising the random effects model does suggest a beneﬁt for pacli-
taxel-platinum of borderline signiﬁcance (hazard ratio for Received 1 August 2002; accepted 5 August 2002
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www.bjcancer.comprogression free survival of 0.84, 95% conﬁdence intervals of 0.70
and 1.01, P=0.06). At this time it is therefore reasonable to
continue to offer paclitaxel along with carboplatin to appropriate
patients as ﬁrst-line therapy, using schedules in widespread usage.
This should be accompanied by a careful explanation of the rela-
tively modest likely beneﬁt in addition to carboplatin. More
important still will be the entry of such patients into appropriate
ﬁrst line chemotherapy studies. These should aim to address issues
such as those described above, so that these dilemmas in manage-
ment can be resolved as soon as possible. The thousands of
patients who have taken part in the trials described, and their
families, deserve nothing less.
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